25/04/2026
// Good news//
We are truly excited to share that our student’s academic work has been published in a Springer Nature journal!
Take a look 👉 https://link.springer.com/article/10.1007/s00262-026-04372-5
Special thanks to Professor Tsung-I Hsu (The Ph.D. Program for Neural Regenerative Medicine, Taipei Medical University) for his dedicated mentorship. He guided our Indonesian student, Jack (Bahagia Willibrordus Maria Nainggolan), in completing a solid and impactful research project, which was successfully published in Springer Nature this April. Achieving this milestone within just three months reflects not only the student’s effort, but also the strength of the academic training system and research environment.
The New Southbound Program is designed with an intensive 3-month academic training model. Students are embedded directly into research teams, focusing deeply on a specific topic. In addition, they have opportunities to enroll in credit-based courses to broaden their medical knowledge, and to engage in institutional visits that foster meaningful academic and cross-cultural exchange.
This outcome demonstrates that with the right structure, resources, and mentorship, talent development can be both accelerated and tangible.
We will continue to refine and invest in this model, with the goal of nurturing more globally competent healthcare professionals.
-------------------------------------------------------------------------
//好消息//
印尼學生JACK學術成果登上 Springer Nature 期刊啦！
一起欣賞 👉 https://link.springer.com/article/10.1007/s00262-026-04372-5
特別感謝 徐宗溢教授（臺北醫學大學神經再生醫學博士學位學程），不僅帶領來自印尼的學生 Jack（Bahagia Willibrordus Maria Nainggolan）完成一篇扎實且具深度的學術報告，更成功投稿至 Springer Nature 並於今年四月發表。短短三個月內達成這樣的成果，這不只是個人努力的展現，更是團隊教學與研究能量的具體體現。
新南向專案在學術訓練設計上，採取密集且高度整合的三個月培訓模式。學生將實際進入指導教授的研究團隊，聚焦一個主題進行深入研究；同時，也可透過學分課程拓展醫學領域的多元知識，並透過醫療機構參訪，促進跨文化與專業的深度交流。這樣的設計，不只是學習，更是實戰與產出的結合。
這次的成果再次驗證，當資源、制度與教學現場有效對接，人才培育是可以被加速且具體實現的。
未來，我們也會持續優化這樣的培育模式，投入更多心力，培養具備國際視野與專業能力的醫療人才。
Aggressive brain tumors such as glioblastoma (GBM) remain among the most lethal human cancers, with a median survival of only 15 months despite multimodal treatment. Their resistance arises from a triad of barriers—the blood–brain barrier (BBB), marked intratumoral heterogeneity, and a profoundl...
